Compare GEVO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | TRDA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.8M | 274.5M |
| IPO Year | 2010 | 2021 |
| Metric | GEVO | TRDA |
|---|---|---|
| Price | $1.45 | $6.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.58 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 3.4M | 338.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $711,000.00 | ★ $25,421,000.00 |
| Revenue This Year | $19.44 | $39.97 |
| Revenue Next Year | $5.59 | $50.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.12 | $4.93 |
| 52 Week High | $2.97 | $16.45 |
| Indicator | GEVO | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 43.89 |
| Support Level | $1.37 | $5.75 |
| Resistance Level | $1.57 | $7.19 |
| Average True Range (ATR) | 0.08 | 0.54 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 44.44 | 16.06 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.